GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
Takeda/Lilly’s $9B Actos Verdict
A Louisiana jury this week awarded a staggering $9 billion in punitive damages to the companies behind Actos (Pioglitazone HCl). Takeda Pharmaceutical and its partner from 1999–2006, Eli Lilly, have promised to appeal the decision, which came after the jury decided in favor of plaintiff Terrence Allen of Attica, N.Y., who blamed Actos for causing his bladder cancer after taking the drug for five years. The jury’s decision came in part after hearing that Takeda lost or destroyed documents compiled by 46 current and former employees and sales representatives involved in marketing Actos.